

# Brazil: the best choice for Clinical Trials

BIO International Convention 2026



# Executive summary



**Abnacro**, the Brazilian Association of CROs, presents the characteristics of Brazil that make it an excellent country for conducting clinical studies.

- Brazil is a large country, both in size and in number of inhabitants
- Sixth most populous country in the world, with high ethnic and genetic variability
- Stable economy for over 20 years
- One of the top 10 pharmaceutical markets in the world
- Great availability of professional health workforce and excellent infrastructure in the sector
- Top Universities: 14 Brazilian Universities among the top 20 in Latin America
- Scientific publications: top 20 in the world ranking of articles and citations
- Robust and well-established ethical-regulatory system
- Long history of conducting clinical trials since the 1980s
- Brazil can be the basis for carrying out multicenter studies in other Latin American countries
- Approval of "the Clinical Research Act" (14.874/2024)
- Sponsors benefit from a predictable parallel review process with competitive timelines: 90 business days at ANVISA (regulatory agency) and 30 at the Ethical Authority.

We are **Abracro**:  
the Brazilian  
Association  
of CROs



20-year celebration!



# Members

## CROs



# Members

## Logistics



## Sites



## Strategic partner



# Members

## Other services

AstraZeneca 

 Bristol Myers Squibb®

epHealth



Assessoria Aduaneira

GSK



JCR do Brasil  
Farmacêuticos

 Grupo Fleury

Johnson & Johnson

Lefosse

*Lilly*  
A MEDICINE COMPANY

pga+

PINHEIRONETO  
ADVOGADOS

poloTrial

Roche


# General Data

**6th most populous country in the world**

Population: 213,196,304 (ref. year: 2020)

**5th largest country in the world (by land area)**

Area: 8.5 million km<sup>2</sup> (40% larger than Europe without Russia)



# General Data

There are three predominant types of climate in the country: **equatorial**, **tropical** and **temperate**.



Equatorial




Tropical



Temperate

# Characteristics of the population



**Population Pyramid**  
(opportunity to study various diseases)

**Brazilian genomes address lack of diversity and have potential for new findings.**

**500 Years of admixture of Native American, African and European populations.**


**Largest population of African descent outside of Africa, including admixtures not found in Africa.**

**Ethnic and Genetic characteristics**

# Economy / Politics

- GDP: **9th largest economy** (2019, pre-pandemic)
- Inflation in Brazil in the last 20 Years (**stable scenario**)
- Brazil is the **4th largest democracy** in the world in terms of population
- Brazil is a presidential federative republic, with state power divided into **Executive, Legislative** and **Judiciary**.

**Inflation in Brazil the last 20 years (monthly, %)**



# Pharmaceutical Market

2016			2021			2026		
RK	País	% dos EUA	RK	País	% dos EUA	RK	País	% dos EUA
1	Estados Unidos	100	1	Estados Unidos	100	1	Estados Unidos	100
2	▲ China	28	2	China	29	2	China	29
3	▼ 1 Japão	19	3	Japão	15	3	▲ 1 Alemanha	12
4	Alemanha	11	4	Alemanha	11	4	▼ 1 Japão	12
5	França	8	5	França	7	5	França	7
6	Itália	7	6	▲ 1 Reino Unido	6	6	▲ 1 Brasil	7
7	Reino Unido	6	7	▼ 1 Itália	6	7	▼ 1 Reino Unido	6
8	Espanha	5	8	▲ 1 Brasil	6	8	▼ 1 Itália	6
9	Canadá	5	9	▼ 1 Espanha	5	9	▲ 1 Índia	6
10	▲ 2 Brasil	4	10	▼ 1 Canadá	5	10	▼ 1 Espanha	5
11	▲ 2 Índia	3	11	Índia	4	11	▼ 1 Canadá	5
12	▼ 1 Austrália	3	12	▲ 2 Rússia	3	12	Rússia	4
13	▼ 3 Coreia do Sul	3	13	Coreia do Sul	3	13	Coreia do Sul	3
14	▲ 1 Rússia	2	14	▼ 2 Austrália	3	14	▲ 1 México	3
15	▼ 1 México	2	15	México	2	15	▲ 1 Turquia	2

## CLINICAL TRIALS IN BRAZIL

Hands on  
for physicians

Relationship with  
decision makers of  
the health sector

Rankings using constant USD with Q2 2020 exchange rates, except Argentina using USD due to hyperinflation.

# Characteristics of the Health Sector in Brazil

**53 million** beneficiaries of private health care plans <sup>1</sup>

About **160 million** people depend exclusively on SUS (Brazilian Health System)

Source: Agência Nacional de Saúde Suplementar. <http://www.ans.gov.br/perfil-do-setor/dados-gerais>

# Characteristics of the Health Sector in Brazil

- 302 thousand Pharmacists <sup>1</sup>
- 693 thousand Nurses <sup>2</sup>
- 1,6 million Nursing Technicians <sup>2</sup>
- 425 thousand Nursing Assistants <sup>2</sup>
- 452 thousand Physicians <sup>3</sup>
- 100 Thousand Biomedic
- In addition to many biologists, physiotherapists, dentists, etc.

- Physicians
- Biomedic
- Pharmacist
- Nurses

Main health professionals who make up the team of a study site.



1. Conselho Federal de Farmácia. <https://site.cff.org.br/estatistica>
2. Conselho Fh <http://www.cofen.gov.br/enfermagem-em-numeros>
3. Conselho Federal de Medicina. [https://portal.cfm.org.br/index.php?catid=3&id=27500%3A2018-03-19-19-09-56&option=com\\_content&view=article#:-:text=O%20Brasil%20contava%2C%20em%20janeiro.91%20por%20grupo%20de%20mil](https://portal.cfm.org.br/index.php?catid=3&id=27500%3A2018-03-19-19-09-56&option=com_content&view=article#:-:text=O%20Brasil%20contava%2C%20em%20janeiro.91%20por%20grupo%20de%20mil).
4. Revista do Biomédico: [https://crbm1.gov.br/site2019/wp-content/uploads/2021/05/Arte\\_BiomedicinaMundo\\_L\\_bx2.pdf](https://crbm1.gov.br/site2019/wp-content/uploads/2021/05/Arte_BiomedicinaMundo_L_bx2.pdf)
5. ederal de Enfermagem.

# Characteristics of the Health Sector in Brazil



**140 thousand** health establishments



Employs **more than 6 million** people (7% of the total workforce)



**453 thousand** beds



**53,5%** in assistance activities



**46,5%** in other sectors activities, such as the pharmaceutical industry, service providers, etc.

# Universities

## Education and Research

**14 Brazilian Universities**  
among the top 20 in  
Latin America

Sources: Ranking da Times Higher Education (THE), 2022.  
<https://www.bbc.com/portuguese/geral-62150335>





# Ranking of Scientific Publications

## Scimago Journal & Country Rank

Data from year 1996 to 2021

Country	↓ Documents
1  United States	14408686
2  China	8254736
3  United Kingdom	4235739
4  Germany	3663812
5  Japan	3191326
6  France	2521133
7  India	2353282
8  Italy	2197985
9  Canada	2146402
10  Australia	1747456
11  Spain	1731575
12  Russian Federation	1472666
13  South Korea	1400127
14  Brazil	1233706
15  Netherlands	1190268

#Documents

Country	↓ Citations
1  United States	422391431
2  United Kingdom	114392159
3  China	96129346
4  Germany	89183196
5  France	61010667
6  Canada	58973452
7  Japan	59922910
8  Italy	49903041
9  Australia	43564203
10  Netherlands	39427592
11  Spain	36529229
12  Switzerland	26332969
13  India	24290014
14  Sweden	23272197
15  South Korea	19426697
16  Belgium	1699195
17  Brazil	15613319

#Citations

# Experience: the history of Brazil in clinical research

- Pioneering in **HIV Research** in the 80's (Dr. David Uip, Dr. Mauro Schechter, Dr. Jamal Suleiman, among others)
- Outstanding quality and recruitment rate in **cardiology and endocrinology clinical trials** in the 90's and early 2000's
- Great increase in the number of **clinical studies in several areas**, e.g., Onco-Hematology and Rare Diseases from the beginning of the 2000s to the present day.



# Anvisa – Brazilian Health Regulatory Agency

- The health regulatory agency is internationally recognized for its rigorous regulation of clinical studies.
- Anvisa has been part of the ICH management committee since 2019.
- Is the only authority in Latin America in this position.



# Covid-19 in Brazil

- **Intensive participation** in clinical trials with C-19 vaccines
- **High quality data** generation in record time
- **Over 40,000** survey participants
- Approx. **50 research** sites

## Clinical studies conducted in Brazil with vaccines against C-19:

Chadox 1 NCOV 19 * (Astrazeneca)	Coronavac (Butantan) *
Comirnaty (Pfizer/Wyeth) *	INO-4800 (Icon plc)
Janssen Vaccine (Janssen-Cilag) *	AZD2816 (AstraZeneca)
Butanvac (Butantan)	COVLP (Medicago)
Inativada contra Sars-CoV-2 (IMBCAMS)	SCB-2019 (Clover)
Vacina de RNAm para Sars-CoV-2 (Sanofi Pasteur)	Vacina de RNA MCTI Cimatec HDT (HDT Biocorp/Cimatec-BA)
Ad26.COVS.S (Janssen)	Covaxin (Precisa) Estudo cancelado
SpiNTec (UFMG)	

Source: <https://www.gov.br/anvisa/pt-br/assuntos/paf/coronavirus/vacinas/estudos-clinicos>

# “The Clinical Research Act”

- Approval of the Clinical Research Act (14.874/2024), taking effect on August 27<sup>th</sup>, 2024.
- Adds **reliability and predictability** to its already solid environment for clinical research conduction
- **Competitive timelines** (clinical trial applications):
  - Anvisa: 90 business days
  - Ethical Authority (CEP): 30 business days

# INAEP National Instance of Ethics in Research

## Local Ethics Committees accredited, certified



**915**  
ethics  
committee

A nationwide network  
committed to  
research ethics.

### INAEP LEADERSHIP

As a diverse technical collegiate body



Diversity of  
areas and expertise



Impartiality and  
independence



Technical and  
scientific rigor



Commitment to  
society



Ethics, protection  
and respect  
for dignity

**ETHICAL APPROVAL  
OF CLINICAL STUDIES  
IN BRAZIL IS UNIQUE.**

In Brazil,  
ethical approval  
of clinical studies  
is carried out  
**ONLY ONCE.**



Efficiency, harmonization  
and protection for  
research participants.

# A gateway to studies in Latin America

- . Mexico
- . Peru
- . Colombia
- . Chile
- . Argentina

# Conduct your clinical studies in Brazil!

Brazil brings numerous advantages together for conducting clinical studies:



**Large population**



**Ethnic diversity**



**Competitive costs**



**Quality and prominence  
in conducting trials**



**Advanced medical  
infrastructure**



**High standard  
regulation**

# Contacts



info@**abracro**.org.br



facebook.com/**abracro**



sptfy.com/**abracro**



linkedin.com/company/**abracro**



@**abracro\_oficial**



www.**abracro**.org.br



www.youtube.com/c/**abracro**